



ROBERT PAYDON

PARTNER

London, England

+44 20 7539 7280

rpaydon@atllp.co.uk



Robert Paydon is an experienced commercial litigation/dispute resolution lawyer with more than 25 years of experience. He leads the firm's U.K. commercial litigation practice area. Robert advises on a wide range of contentious matters, including in the pharmaceutical/life sciences, manufacturing, natural resources and property sectors.

He deals with contractual, company and shareholder disputes, as well as regulatory issues (for example, matters concerning the U.K.'s Pharmaceutical Price Regulation Schemes and advertising). Robert acts for clients from the U.K. and overseas, and much of his work has a multi-jurisdictional aspect.

Robert has advised on a range of insolvency issues and acts for creditors, debtors and office holders, and he is also concerned with the protection and management of corporate and individual reputations, particularly through the law of defamation, privacy and data protection.

Robert's experience covers the full extent of the litigation process, from risk management and pre-action advice through to obtaining and resisting interim orders, trial, proceedings in the appellate courts and enforcement, as well as significant involvement in international arbitration and alternative dispute resolution (ADR) processes, including mediation and expert determination both as party adviser and as counsel to the expert.

Robert is a recognised lawyer in the field of Commercial Litigation, most recently in the 2021 edition of the Legal 500 UK.

BACKGROUND

Prior to joining Armstrong Teasdale, Robert served as head of commercial litigation at Kerman & Co. He joined Armstrong Teasdale in early 2021 when the firm combined with Kerman & Co. Before that, he worked in private practice for a number of other London law firms, including as the head of litigation for the U.K. office of a leading Canadian law firm.

EDUCATION

- BPP University Law School (1996)
 - Law
- Nottingham Law School (GDL, 1995)

SERVICES AND INDUSTRIES

Alternative Dispute Resolution
Restructuring, Insolvency and Bankruptcy
Litigation
Complex Commercial Litigation
Life, Health, Disability and ERISA Litigation
Consumer Products and Services
Energy and Utilities
Health Care and Life Sciences
Manufacturing and Innovation

ADMISSIONS

England and Wales

- Law
- University of Leicester (B.A., *Hons*, 1993)
 - Politics

CHARITABLE AND CIVIC INVOLVEMENT

- High-profile U.K. charity (Volunteer)
- Primary School (Former Parent Governor)

ACCOLADES

- The Legal 500, Recommended Lawyer, Commercial Litigation: Mid-Market (2021-present); Oil & Gas (2022); Dispute Resolution (Previous ranking)
- Chambers & Partners U.K., Dispute Resolution (Previous ranking)

LANGUAGES

- French

EXPERIENCE

Secured Dismissal for Pharmaceutical Client in High Court Case

Secured dismissal of a case before the High Court in which the claimant alleged that it had reached a legally binding agreement with our client, a Mumbai-headquartered pharmaceutical company, for the supply of drug for the Canadian market.

\$200 Million Arbitration Proceedings for Breach of Contract

Acted for an African natural resources company in \$200 million LCIA arbitration proceedings concerning a breach of contract.

Acted for Client in Connection with Preference, Undervalue Transaction Claims

Acted for a U.K. company in connection with preference and undervalue transaction claims threatened against it by an administrator.

Advised Leading International Business in Issues Related to a U.K. Social Media Campaign

Advised a leading international business concerning issues arising out of its proposed U.K. social media campaign.

Advised on Division of Multinational Business Including Parallel Proceedings in the U.K. and U.S.

Advised on a high-value dispute concerning the division of a multinational business (with parallel proceedings in the High Court in London and across the U.S.).

Advised Overseas Pharma Company in Defense of High Court Proceedings

Advised a leading overseas pharma company in its defense of significant High Court proceedings.

Advised Pharma Companies on U.K.'s Pharmaceutical Price Regulation Schemes

Advised several pharmaceutical companies about matters concerning the U.K.'s Pharmaceutical Price Regulation Schemes.

Advised U.K. Pharma Company in Defamatory Reporting Case

Advised a U.K. pharmaceutical company concerning defamatory reporting in the media about one of its key products.

Defense in \$100 Million Proceedings in English Commercial Court

Acted for a defendant in \$100 million proceedings in the English Commercial Court.

Shareholders Dispute for Ultra High-Net-Worth Individual

Advised an ultra high-net-worth individual in a significant multi-jurisdictional shareholders dispute.

THOUGHT LEADERSHIP

September 21, 2021

Company Directors Beware! Parliament Debates Extending Current Directors' Disqualification Regime to Directors of Dissolved Companies

September 28, 2020

Innovation and modernization in the court system and in arbitration as a result of COVID-19

Kerman & Co. website

June 12, 2020

Insolvency proceedings and the Coronavirus

Kerman & Co. website

March 30, 2020

A lifeline to businesses: changes promised to the 'wrongful trading' provisions of current UK Insolvency legislation

Kerman & Co. website

March 5, 2020

Cryptocurrency fraud: The High Court strikes back

Kerman & Co. website

February 6, 2020

The choice of English law as the governing law of your international contract following Brexit

Kerman & Co. website